Old Web
English
Sign In
Acemap
>
Paper
>
Structural and symptomatic benefit of a half-live extended, systemically applied anti-ADAMTS-5 inhibitor (M6495)
Structural and symptomatic benefit of a half-live extended, systemically applied anti-ADAMTS-5 inhibitor (M6495)
2018
C. Brenneis
B. Serruys
T. Van Belle
S. Poelmans
K. Kleinschmidt-Doerr
Hans Guehring
M. Michaelis
S. Lindemann
Keywords:
Physical therapy
Medicine
Cardiology
ADAMTS
Internal medicine
Oncology
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
2
Citations
NaN
KQI
[]